Scandion Oncology A/S (STO:SCOL)
Sweden · Delayed Price · Currency is SEK 0.0041
-0.0027 (-39.71%)
Inactive · Last trade price on Jul 11, 2025
Scandion Oncology Company Description
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer.
Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer.
The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.
The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Scandion Oncology A/S
| Country | Denmark |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Francois Martelet |
Contact Details
Address: Symbion Copenhagen, 2100 Denmark | |
| Phone | 45 38 10 20 17 |
| Website | scandiononcology.com |
Stock Details
| Ticker Symbol | SCOL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061031895 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Francois Regis Martelet M.D. | Chief Executive Officer |
| Jan Stenvang M.S., Ph.D. | Chief Scientific Officer |
| Johnny Stilou M.S. | Chief Financial Officer |
| Morten Nissen | General Counsel |
| Mads Kronborg | Head of External Communication |